Home » Topics » Dermatologic, BioWorld Science

Dermatologic, BioWorld Science
RSS

Leo Pharma begins phase IIa study of LEO-138559 for moderate to severe atopic dermatitis

July 27, 2021

PolarityTE submits IND for SkinTE in chronic cutaneous ulcers

July 27, 2021

Gilead studies GS-5718 in phase Ib for cutaneous lupus erythematosus

July 23, 2021

Dosing commences in phase II study of STP-705 for keloid scar prevention

July 15, 2021

Escient reports phase I data on EP-547 for pruritus associated with cholestasis and uremia

July 15, 2021

HT-003 reduces expression of inflammatory cytokines in acne therapeutic model

July 15, 2021

FDA clears IND for Kintor's GT-20029 for androgenetic alopecia and acne

July 14, 2021

Tyrosine-protein kinase ITK/TSK inhibitors discovered at Pfizer

July 14, 2021

EscharEx debridement agent demonstrates efficiency, safety in chronic wound study

July 13, 2021

FDA clears initiation of phase II trial of pyrilutamide in androgenetic alopecia

July 12, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 16, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...